- Lupin’s net income for the fourth quarter hit 3.59 billion rupees, up 52% year on year but missed the estimated 5.2 billion rupees.
- The total revenue was 49.6 billion rupees, a 12% increase year on year, although slightly below the anticipated 50.92 billion rupees.
- Total costs for the quarter were 44.9 billion rupees.
- The finance cost reduced by 23% year on year to reach 712.9 million rupees, below the estimated 791.4 million rupees.
- Other income for the quarter was at 292.5 million rupees, a drop of 22% year on year.
- Lupin declared a dividend of 8 rupees per share.
- Out of all the ratings, the company got 12 buys, 13 holds, and 14 sells.
- This financial data comparison is based on values reported by Lupin from their original disclosures.
A look at Lupin Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Lupin Ltd shows a promising long-term outlook. The company scores well across multiple factors, with a strong momentum score of 4, indicating positive market momentum. Additionally, Lupin Ltd demonstrates solid value, growth, and resilience scores of 3, suggesting a stable financial foundation and growth potential.
Lupin Limited, a manufacturer of bulk actives and formulations, has a diversified product portfolio that includes anti-TB medications, anti-infectives, cardiovascular drugs, and phytomedicines. With favorable scores in key areas such as momentum and value, Lupin Ltd appears well-positioned for future growth and stability in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
